FDA Grants Soterix Medical IDE Approval For Home-Based tDCS-LTE Trial For Depression

Soterix Medical Inc. announces it has received Investigational Device Exception (IDE) from the U.S. Food and Drug Administration (FDA) to launch a trial of transcranial Direct Current Stimulation-Limited Total Energy (tDCS-LTE) neuromodulation at-home for individuals with major depressive disorder. Soterix Medical developed proprietary technology supporting reliable home-based tDCS including the single-use SNAPpad™ electrodes that ensure clean and tolerated therapy at-home, and the ElectraRx™ digital health care platform that provides caregivers ongoing insight on consumer response and full control of ongoing therapy.

Soterix Medical Inc. was formed to develop and deploy innovative medical treatments . . .